We Need Less Gov't Involvement in Drug Prices

We should be wary of highly disruptive “reforms” in an effort to modulate spikes in the price of a relatively small number of troubling outliers. Prescriptive industry-wide requirements could have serious unintended consequences on the overall health of the U.S. pharmaceutical industry and the future availability of drugs for Americans. For example, establishing new U.S. governmental price controls would add yet another level of time-consuming bureaucratic review, provide new opportunities for companies to game the government regulations for competitive advantage, and discourage corporate investment and marketing in the United States. The net effect would likely be to delay or preclude access to new medical products.